Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verekitug in Severe Asthma (VALIANT Extension)
NCT06966479Phase 2Active, not recruiting
- Sponsor
- Upstream Bio
- Start
- May 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of vereckitug in severe asthma, sponsored by Upstream Bio. Started May 2025; status: active, not recruiting.
02
Drugs
vereckitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT06966479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966479.